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Sequencing samples of melanoma for targetable mutations has become a
standard of care for metastatic disease. In this issue, Siroy et al. demonstrate
how clinical genetic analysis is moving from a single-gene Sanger-sequencing
approach to targeted next-generation sequencing. They present data on a large
cohort of patients with advanced melanoma, and their data support previous
findings and also present novel aspects of melanoma genetics.
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With the introduction of targeted thera-
pies such as BRAF V600 inhibitors
for metastatic melanoma, sequencing
tumor samples for the presence of tar-
getable mutations has become clinically
routine. Conventional genetic analysis
techniques have relied on Sanger-
sequencing selected gene mutations for
choosing targeted therapies. Although
next-generation sequencing approaches
have greatly helped to understand the
landscape of genetic mutations in mel-
anoma, their application was until
recently restricted mainly to research,
in particular because freshly frozen,
unfixed tissue was required for analysis.
The approach presented in this issue by
Siroy et al. (2014) has now gained
momentum for a number of different
cancers. Focused next-generation seq-
uencing panels now cover clinically
relevant genes, enabling one to obtain
reliable results even with DNA isolated
from routine pathology formalin-fixed,
paraffin-embedded (FFPE) samples.
Arguably, this approach to sequencing
panels of selected genes will be useful
for a good number of years, because
larger, more comprehensive analyses
such as whole-exome or whole-genome
sequencing require considerably more
financial and bioinformatic resources
and because the large amount of
additional data that are acquired are
(at least for the moment) not clinically
relevant.
The study by Siroy et al. (2014)
applies a pan-cancer panel covering
46 genes to an impressively large
cohort of 699 melanoma samples.
The cancer panel employed covers not
entire genes, but focuses on areas where
hot spot mutations are known to occur.
From a clinical perspective this is
certainly a valid approach, as currently
only a number of well-known activating
mutations in melanoma can be targeted
therapeutically, and all of these were
covered by the applied sequencing
panel.
Distribution of driver mutations in
melanoma
The distribution of mutations detected in
the study among the different melanoma
subtypes fits well with previous reports
(Curtin et al., 2005; Hodis et al., 2012;
Krauthammer et al., 2012). Cutaneous
(non-acral) melanomas were found to
have BRAF mutations in 40–50% and
NRAS mutations in B20% of cases. A
remarkably similar mutation distribution
was noted in the relatively large number
of melanomas of unknown primary
(MUP—104 samples). As expected, in
acral and mucosal melanomas, lower
percentages of BRAF mutations
(19 and 7%, respectively), comparable
See related article on pg 508 percentages of NRAS mutations (24 and
21%, respectively), and higher percen-
tages of KIT mutations (11 and 16%,
respectively) were identified. The fre-
quency of the various mutations identi-
fied in each oncogene fits well with
previous studies; however, because of
the large cohort of samples analyzed,
the Siroy et al. (2014) study enables a
more detailed overview of the
distribution of less common mutations,
including rarer BRAF V600 (non-V600E)
mutations and non-V600 BRAF
mutations (Supplementary Figure 3).
Melanomas harboring non-V600 BRAF
mutations were found to harbor
concurrent mutations in RAS genes
relatively frequently. It is noteworthy,
that aside from NRAS, Siroy et al.’s
screen also picked up KRAS and HRAS
mutations. With 15 tumors having KRAS
and 7 HRAS mutations, of which 11
(73%) KRAS and all 7 HRAS mutations
were clearly activating (codon 12, 13, or
61 alterations), this group represents a
relevant number of activating mutations
(2–3% of tumors) that have in general
been neglected by earlier conven-
tional Sanger-sequencing analyses. The
clinical and therapeutic impact of such
mutations will need to be determined in
future studies.
TP53 mutations in melanoma
The occurrence of mutations in TP53 in
melanoma was known; however, com-
pared with other tumor suppressors such
as CDKN2A and PTEN, its role in
melanoma pathogenesis has been
underappreciated. In part, this was due
to earlier studies reporting low-TP53
mutation frequencies (Albino et al.,
1994). In addition, in contrast to tumor
suppressors such as CDKN2A and
PTEN, where frequent copy number
losses highlight their role as tumor sup-
pressors, copy number losses appear to
be relatively rare in TP53 where muta-
tions are apparently a more frequent
genetic alteration (Curtin et al., 2005).
The report by Siroy et al. (2014)
nicely demonstrates the rate and distri-
bution of TP53 mutations in melanoma.
The overall mutation frequency of 16%
in all samples analyzed supports a
significant role for TP53 in melanoma
pathogenesis. Further, Siroy et al. (2014)
identify a characteristic distribution of
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TP53 mutations among melanoma
subtypes, with acral and mucosal
melanomas having lower frequencies
of mutations compared with cutaneous
(non-acral) and MUP cases. This
distribution, together with the higher
prevalence of mutations found among
tumors arising on the head and neck,
as well as the frequent UV-signature
mutations observed, strongly points
toward UVR as the major factor for
inducing TP53 mutations in melanoma.
These findings, together with other
recent genetic reports and experi-
mental data (Hodis et al., 2012;
Krauthammer et al., 2012; Viros et al.,
2014), support a larger, hitherto
underappreciated, role for TP53 in
melanoma, which warrants further
investigation.
General impact and perspective
The study by Siroy et al. (2014)
contributes to the field, both from
research and clinical perspectives. The
data allow a number of genetic altera-
tions in melanoma to be seen in a larger
context, in particular in their association
with different melanoma subtypes.
Perhaps one of the most striking results
is the comparable distribution of BRAF,
NRAS, and TP53 mutations in MUP
and cutaneous (non-acral) melanomas.
This finding clearly points toward
MUP as having a cutaneous (non-acral)
origin. This conclusion is supported by
other studies (Griewank et al., 2014)
and argues strongly against excluding
MUPs from clinical studies testing
new drugs in advanced cutaneous
melanoma.
From a diagnostic perspective, the
Siroy et al. (2014) study presents a
model for a relatively simple, clinically
valuable, next-generation sequencing–
based genetic analysis of melanoma
samples. Utilizing an established, com-
mercial setup with a standardized
cancer panel and analyzing DNA iso-
lated from standard routine FFPE mate-
rial, this kind of approach could find a
broader clinical application base and
not necessarily be limited to large
institutions.
Strengths of the applied sequencing
panel and analysis are that all currently
relevant targetable gene mutations
for standard therapies (BRAF, NRAS,
and KIT) are picked up. In addition,
genes that generally have not been
covered by conventional Sanger
approaches, such as TP53, KRAS, and
HRAS, are analyzed. The co-occurrence
of these mutations was also documented
in detail, which is new for a cohort of
this size.
In the future, this type of genetic
screen could be of even more
value for melanoma patients if a
panel were applied focusing on gene
alterations known to be relevant to
melanoma. The majority of genes
analyzed in the pan-cancer panel
applied in the study have little or no
known role in melanoma pathogenesis.
Although Siroy et al. (2014) did
find an occasional mutation in many
of these genes, they are most likely
passenger mutations having no appre-
ciable role in the tumors’ pathogenesis
and no therapeutic relevance. The
commercial pan-cancer panel applied
in the study has in the meantime
been updated to include genes
such as GNAQ or GNA11 mutations,
which would have been of value
for the uveal melanoma samples (Van
Raamsdonk et al., 2010). How-
ever, many other melanoma-relevant
genes are still missing. Examples
would be mutations or alterations in
RAC1, NF1, BAP1, the TERT pro-
moter, etc. (Hodis et al., 2012;
Krauthammer et al., 2012; Horn et al.,
2013; Huang et al., 2013; Griewank
et al., 2014).
The best solution would be to employ
a melanoma-specific sequencing panel
instead of one that covers mutations
relevant to many cancer entities. Efforts
to design such a commercial panel
focused on genetic alterations in mela-
noma are already under way. Opti-
mally, this sort of assay will not only
detect mutations but also be able to pick
up copy number alterations, which are
relevant both for certain activating
events such as KIT amplifications or
gains of CCND1, as well as loss of
function events, such as losses of PTEN
or CDKN2A (Curtin et al., 2005).
Further development of a panel that
also recognizes genetic mechanisms of
resistance to available therapies would
be especially valuable for clinicians
who treat patients with metastatic
disease.
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Clinical Implications
 Sequencing melanoma samples for a panel of frequently mutated genes
can be expected to become a standard diagnostic procedure.
 TP53 mutations are common in melanoma.
 The genetic profile of melanoma of unknown primary supports a
cutaneous origin.
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